Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED AUGUST 2019 . Refer to TA604: Idelalisib for treating refractory follicular lymphoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | idelalisib (Zydelig®) | ||
| Formulation | 100 mg, 150 mg film-coated tablet | ||
| Reference number | 2597 | ||
| Indication | Treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 0717 | ||
| NMG meeting date | 08/02/2017 | ||
| AWMSG meeting date | 15/03/2017 | ||
| Date of issue | 03/04/2017 | ||
| NICE guidance | TA604: Idelalisib for treating refractory follicular lymphoma |
||